This greenfield facility, Sami Nutraceuticals Pvt. Ltd., will serve the nutraceutical and pharmaceutical majors in various regulated markets globally
Sami-Sabinsa Group, a multi-national health science company, headquartered in Bengaluru, unveiled the new state-of-the-art Unit -1 manufacturing facility at Hassan, India. This greenfield facility, Sami Nutraceuticals Pvt. Ltd., will serve the nutraceutical and pharmaceutical majors in various regulated markets globally. Sami-Sabinsa has boosted its annual throughput to over 2000 tons and the combined plant area to 1.75 million square feet with the addition of Sami Nutraceuticals, which is the company’s ninth manufacturing facility. In addition, the Group is in the final phases of completion of its Unit-2 manufacturing facility at Hassan, India which should be completed by December 2023.
With customer centricity as its brand’s essence, the company has expanded its presence into several promising geographies globally, including the UK, France, Hungary, and Spain in Europe added to offices in Germany and Poland. Through global expansion, the company intends to stay close to its customers and understand their needs better. Sami-Sabinsa Group has a workforce of over 1,400 employees globally, across 17 countries, with multiple key associates having more than 25 years of in-house experience.
In Intellectual Property (IP) to support its ingredients, Sami-Sabinsa has set the standard for decades. The IP infrastructure and team of Sami-Sabinsa Group spans over U.S.A, Europe, Canada, and India. The current suite of patents exceeds 440, including the US and other countries, which have enabled its novel ingredients to take the lead in international markets. The company was the first to commit to research and publish studies in support of product safety and efficacy, long before this was considered an essential part of developing a branded ingredient. And the company has worked hard to set the standard for best practices throughout the global industry.
